Skip to main content
Canada’s most-awarded newsroom for a reason
Enjoy unlimited digital access
$1.99
per week
for 24 weeks
Canada’s most-awarded newsroom for a reason
$1.99
per week
for 24 weeks
// //

Bellus Health Inc TSX: BLU-T

Today's Change
Volume
Real-Time Last Update TSX Last Sale

More stories below advertisement

Latest Press Releases

BELLUS Health Announces Completion of Patient Enrollment in SOOTHE Phase 2b Trial for Refractory Chronic Cough and BLUEPRINT Phase 2a Trial for Chronic Pruritus Associated with Atopic Dermatitis
- Business Wire - Thu Sep 23, 6:00AM CDT
Business Wire - CMTX
Thu Sep 23, 6:00AM CDT
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced that the Company has completed patient enrollment in the Phase 2b SOOTHE clinical trial of BLU-5937 in refractory chronic cough ("RCC") and the Phase 2a BLUEPRINT clinical trial of BLU-5937 in chronic pruritus associated with atopic dermatitis ("AD"). Topline results from both trials are expected in December 2021.
BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough
- Business Wire - Mon Sep 13, 6:45AM CDT
Business Wire - CMTX
Mon Sep 13, 6:45AM CDT
--Data from interim analysis support accelerated planning for the Phase 3 program
BELLUS Health to Report Additional RELIEF Data in an Oral Presentation at the European Respiratory Society International Congress 2021
- Business Wire - Mon Aug 23, 6:00AM CDT
Business Wire - CMTX
Mon Aug 23, 6:00AM CDT
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other hypersensitization-related disorders, today announced that an abstract covering additional data from the RELIEF Phase 2a trial has been accepted for oral presentation at the upcoming European Respiratory Society ("ERS") International Congress 2021, being held September 5-8, 2021.
BELLUS Health Reports Second Quarter 2021 Financial Results and Business Highlights
- Business Wire - Wed Aug 11, 3:30PM CDT
Business Wire - CMTX
Wed Aug 11, 3:30PM CDT
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the second quarter ending June 30, 2021.
BELLUS Health to Participate in the Jefferies Virtual Healthcare Conference
- Business Wire - Tue May 25, 6:00AM CDT
Business Wire - CMTX
Tue May 25, 6:00AM CDT
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will be participating in a fireside chat at the Jefferies Virtual Healthcare Conference.
Morganti & Co., P.L.C. Announces the Filing of a Securities Class Action on Behalf of Investors Who Acquired Bellus Health, Inc.
- BusinessWire - Sat May 15, 11:44AM CDT
BusinessWire - CMTX
Sat May 15, 11:44AM CDT
Morganti & Co., A pro-investor law firm with licensed and experienced lawyers in Canada and the United States that represent investors announces the filing of a securities class action on behalf of investors who purchased or otherwise acquired common stock of Bellus Health, Inc. ("Bellus" or "Company") (NASDAQ: BLU, TSX: BLU, FWB: BHN0) from September 5, 2019 through July 5, 2020, inclusive (the "Class Period").
BELLUS Health to Participate in the 2021 RBC Capital Markets Global Healthcare Conference
- BusinessWire - Wed May 12, 6:00AM CDT
BusinessWire - CMTX
Wed May 12, 6:00AM CDT
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will be participating in a fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference.
BELLUS Health Reports First Quarter 2021 Financial Results and Business Highlights
- BusinessWire - Mon May 10, 3:30PM CDT
BusinessWire - CMTX
Mon May 10, 3:30PM CDT
--- Ended quarter with US$81.9 million in cash, cash equivalents and short-term investments; current cash position expected to be sufficient to fund operating plan until end of 2022 -
BELLUS Health to Present at the American Thoracic Society 2021 International Conference
- BusinessWire - Mon May 10, 6:00AM CDT
BusinessWire - CMTX
Mon May 10, 6:00AM CDT
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other hypersensitization-related disorders, today announced that three abstracts on BLU-5937 have been accepted for presentation at the upcoming American Thoracic Society ("ATS") 2021 International Conference, being held on May 14-19, 2021.
BELLUS Health to Present at the Bloom Burton & Co. Healthcare Investor Conference
- BusinessWire - Tue Apr 13, 6:00AM CDT
BusinessWire - CMTX
Tue Apr 13, 6:00AM CDT
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company at the Bloom Burton & Co. Healthcare Investor Conference.

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies